Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo - Erlinge, D; Varenhorst, C; Braun, OO (J Am Coll Cardiol, 2008)
et al.